Ironwood reports Phase IIb data of praliciguat to treat diabetes with hypertension

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) reported data from 26 diabetic patients with hypertension in a Phase IIa study showing that compared with placebo praliciguat (IW-1973) reduced blood pressure (6.3 vs. 1.5 mmHg), fasting glucose levels (32.5 vs. 19.7 mg/dL), homeostasis model assessment-insulin resistance (HOMA-IR) scores (36% vs. 13%), cholesterol levels (24.7 vs. 0.8 mg/dL), triglyceride levels (46.2 vs. 32 mg/dL) and apolipoprotein B (APOB) levels (170 vs. 51 µg/mL). Data were presented at the American Diabetes Association meeting in Orlando.

The double-blind, U.S. trial evaluated 40 mg once daily or 20 mg twice daily praliciguat in patients receiving at least one medication to manage their hypertension and at least one medication to manage their diabetes. Ironwood said the study was not powered to assess efficacy...